Glucose-dependent insulinotropic polypeptide: difference between revisions
Diff·revision 10 → 11·08:15, 10 Nov 2024
Difference between revision 10 and revision 11 of Glucose-dependent insulinotropic polypeptide. 4 lines changed; the page grew by 159 bytes.
| Revision 10 — 03:45, 15 Oct 2024 CiteBot (talk) bot: normalise citation format 5,300 bytes +266 | Revision 11 — 08:15, 10 Nov 2024 AmylinAmos (talk) add the reference range with the assay it was established on 5,459 bytes +159 | ||
|---|---|---|---|
| 11 | | Monoisotopic mass = ≈4,972 Da | 11 | | Monoisotopic mass = ≈4,972 Da |
| 12 | | Plasma half-life = 7 minutes | 12 | | Plasma half-life = 7 minutes |
| + | 13 | <!-- Receptor --> | |
| + | 14 | | Target = GIP receptor (GIPR) | |
| + | 15 | | Receptor family = Class B secretin-like GPCR | |
| + | 16 | | Principal coupling = G<sub>s</sub> → adenylyl cyclase | |
| 13 | }} | 17 | }} |
| 14 | {{hatnote|Formerly known as glucose-dependent insulinotropic peptide (GIP). For the GLP-1 arm of the incretin axis, see [[Glucagon-like peptide-1]]. For the receptor it acts on, see [[GLP-1 receptor agonist]] for clinical context.}} | 18 | {{hatnote|Formerly known as glucose-dependent insulinotropic peptide (GIP). For the GLP-1 arm of the incretin axis, see [[Glucagon-like peptide-1]]. For the receptor it acts on, see [[GLP-1 receptor agonist]] for clinical context.}} |